|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-4-21
|
|
pubmed:abstractText |
Venous thromboembolism (VTE) occurs frequently in multiple myeloma patients, especially during induction treatment with thalidomide in combination with anthracyclines and/or dexamethasone. Several coagulation abnormalities have been described in untreated myeloma patients, but these have not been prospectively evaluated during and after treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0145-2126
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1078-84
|
|
pubmed:dateRevised |
2008-10-3
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
|
|
pubmed:affiliation |
Department of Hematology, University Medical Center Utrecht, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
